- Home
- WGRX vs AIDX Comparison
WGRX vs AIDX Comparison
Compare WGRX & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WGRX | AIDX |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Other Pharmaceuticals | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 9.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WGRX | AIDX |
|---|---|---|
| Price | $4.35 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 43.9M | 241.9K |
| Earning Date | 05-21-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.83 |
| 52 Week High | $4.49 | $14.09 |
Technical Indicators
Market Signals| Indicator | WGRX | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 81.97 | 24.43 |
| Support Level | $0.26 | N/A |
| Resistance Level | N/A | $1.66 |
| Average True Range (ATR) | 0.43 | 0.14 |
| MACD | 0.31 | 0.00 |
| Stochastic Oscillator | 95.69 | 1.80 |
Price Performance
Historical ComparisonAbout WGRX Wellgistics Health Inc.
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.